Catalyst Calendar

Thu, Sep 17, 2026

1 updates

4:01 PM

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

New Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll focal seizure and PGTCS patients, respectively Enrollment in X-NOVA2 study in MDD completed with approximately 360 total patients; topline data readout

Enrollment • Phase 2Enrollment milestone Thu, Sep 17, 2026xenon-pharma.com

Tue, Sep 8, 2026

1 updates

XENE

5:00 PM

Mechanistic Characterization of Azetukalner: KV7 Binding, Enhanced Channel Opening, and Rational Polytherapy Potential in Epilepsy

Congress: European Epilepsy Congress (September 6, 2026) Authors: Sankar R, et al.

xenon-pharma.com

Thu, Sep 3, 2026

1 updates

XENE

4:01 PM

Xenon to Present at Wells Fargo Healthcare Conference

VANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced

xenon-pharma.com

Fri, Aug 28, 2026

1 updates

XENE

4:01 PM

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, BC and BOSTON, MA, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced

xenon-pharma.com

Wed, Aug 26, 2026

1 updates

XENE

4:01 PM

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety results New poster will highlight the mechanistic characterization of azetukalner, including its potential additive effects when used with commonly prescribed ASMs VANCOUVER, BC and BOSTON, MA, Aug.

Presentation / Abstract • Phase 3EEC poster presentations Sun, Sep 6, 2026, 2:00 PM EESTxenon-pharma.com

Thu, Aug 6, 2026

1 updates

XENE

4:01 PM

Xenon Reports Q2 2026 Financial Results and Provides Business Update

NDA submission for azetukalner on track for Q3 2026 following pre-NDA meeting with FDA Phase 3 X-TOLE3 study in FOS and X-ACKT study in PGTCS continue to enroll Three Phase 3 studies of azetukalner in neuropsychiatry continue to advance, with topline data from X-NOVA2 study in MDD expected H1 2027

Presentation / Abstract • Phase 3EEC abstract release Sat, Sep 5, 2026xenon-pharma.com

Fri, Jul 31, 2026

1 updates

XENE

4:01 PM

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, BC and BOSTON, MA, July 31, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced

xenon-pharma.com

Thu, Jul 30, 2026

1 updates

XENE

4:01 PM

Xenon to Report Q2 2026 Financial Results on August 6, 2026

VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it

xenon-pharma.com

Thu, Jul 2, 2026

1 updates

XENE

4:01 PM

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, MA, July 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need,

xenon-pharma.com